[1]World Health Organization．GLOBOCAN 2008：Cancer Incidence and Mortality Worldwide．2010．

[2]Siegel R，Naishadham D，Jemal A．Cancer Statistics，2013．CA Cancer J Clin，2013，63（1）：11-30．

[3]Jemal A，Bray F，Center MM，et al．Global cancer statistics．CA Cancer J Clin，2011，61（2）：69-90．

[4]Witkowski ER，Smith JK，Tseng JF．Outcomes following resection of pancreatic cancer．J Surg Oncol，2013， 107（1）：97-103．

[5]李增山，李青．2010年第4版消化系统肿瘤WHO新分类．中华病理学杂志，2011，40（5）：351-354．

[6]American Joint Committee on Cancer（AJCC）TNM Staging of Pancreatic Cancer（2010）．

[7]Nishiyama Y，Yamamoto Y，Yokoe K，et al．Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer．Ann Nucl Med，2005，19（6）：491-497．

[8]Kinkel K，Lu Y，Both M，et al．Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods（US，CT，MR imaging，PET）：a meta-analysis．Radiology，2002，224（3）：748-756．

[9]Farma JM，Santillan AA，Melis M，et al．PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms．Ann Surg Oncol，2008，15（9）：2465-2471．

[10]Kysucan J，Lovecek M，Klos D，et al．Benefit of PET/CT in the preoperative staging in pancreatic carcinomas． Rozhledy，2010，89（7）：433-440．

[11]Kauhanen SP，Komar G，Seppanen MP，et al．A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography，multidetector row computed tomography，and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer．Ann Surg，2009，250（6）：957-963．

[12]Kim MJ，Lee KH，Lee KT，et al．The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer．Pancreas，2012，41（6）：897-903．

[13]Park SS，Lee KT，Lee KH，et al．Diagnostic usefulness of PET/CT for pancreatic malignancy．Korean J Gastroenterol，2009，54（4）：235-242．

[14]Lemke AJ，Niehues SM，Hosten N，et al．Retrospective digital image fusion of multidetector CT and ¹⁸F-FDG PET：clinical value in pancreatic lesions-a prospective study with 104 patients．J Nucl Med，2004，45（8）：1279-1286．

[15]Sperti C，Pasquali C，Decet G，et al．F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts：a prospective study．J Gastrointest Surg，2005，9（1）：22-28．

[16]van Kouwen MC，Jansen JB，van Goor H，et al．FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis．Eur J Nucl Med Mol Imaging，2005，32（4）：399-404．

[17]Buchs NC，Buhler L，Bucher P，et al．Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer：a prospective study．J Gastroenterol Hepatol，2011，26（4）：657-662．

[18]Kitajima K，Murakami K，Yamasaki E，et al．Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer：comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT．Mol Imaging Biol，2010，12（4）：452-459．

[19]Sironi S，Buda A，Picchio M，et al．Lymph node metastasis in patients with clinical early-stage cervical cancer： detection with integrated FDG PET/CT．Radiology，2006，238（1）：272-279．

[20]Sperti C，Pasquali C，Chierichetti F，et al．18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma．J Gastrointest Surg，2003，7（8）：953-959，discussion 959-960．

[21]Nakata B，Nishimura S，Ishikawa T，et al．Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer．Int J Oncol，2001，19（1）：53-58．

[22]Schellenberg D，Quon A，Minn AY，et al．18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy．Int J Radiat Oncol Biol Phys，2010，77（5）：1420-1425．

[23]Eisenhauer EA，Therasse P，Bogaerts J，et al．New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）．European journal of cancer（Oxford，England：1990），2009，45（2）：228-247．

[24]Wahl RL，Jacene H，Kasamon Y，et al．From RECIST to PERCIST：Evolving Considerations for PET response criteria in solid tumors．J Nucl Med，2009，50 Suppl 1（2）：122S-150S．

[25]Heinrich S，Schafer M，Weber A，et al．Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity：results of a prospective phase II trial．Ann Surg， 2008，248（6）：1014-1022．

[26]Choi M，Heilbrun LK，Venkatramanamoorthy R，et al．Using 18F- fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer．Am J Clin Oncol，2010，33（3）：257-261．

[27]Okano K，Kakinoki K，Akamoto S，et al．18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer．World J Gastroenterol，2011，17（2）：231-235．

[28]Matsumoto I，Shirakawa S，Shinzeki M，et al．18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma．Clin Gastroenterol Hepatol，2013，11（6）：712-718．